Email this article Press-reliz Vektibiks v kombinatsii s khimioterapiey v kachestve pervoy i vtoroy liniy terapii znachitel'no udlinyaet period bez progressirovaniya u bol'nykh metastaticheskim rakom tolstoy i pryamoy kishki.
- Authors: - -
- Issue: Vol 11, No 3 (2009)
- Pages: 7-9
- Section: Articles
- URL: https://medbiosci.ru/1815-1434/article/view/26775
- ID: 26775
Cite item
Abstract
На Европейском мультидисциплинарном конгрессе ECCO15/ESMO34, прошедшем 20–24 сентября 2009 г. в Берлине, представлены результаты двухрандомизированных многоцентровых исследований III фазы, в которых изучался Вектибикс (панитумумаб) в комбинации с химиотерапией (режимы FOLFOX и FOLFIRI) в качестве терапии первой и второй линий при метастатическом колоректальном раке (мКРР).
Full Text
##article.viewOnOriginalSite##References
- Product Label.
- Douillard JY, Siena S, Cassidy J et al. Randomized phase 3 study of panitumumab with FOLFOX compared to FOLFOX alone as first - line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. ECCO 15–34th ESMO Multidisciplinary Congress; September 20–24, 2009; Berlin Germany.
- Peeters M, Price T, Hotko Y et al. Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second - line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Presented at: ECCO 15–34th ESMO Multidisciplinary Congress; September 20–24, 2009; Berlin, Germany.
- Van Cutsem E et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy - Refractory Metastatic Colorectal Cancer. J Clin Oncol 2007; 25 (13): 1658–64.
Supplementary files
